Breast Cancer Vaccine – Prioritizing Deterrence

Abstract

The control of the immune system through the administration of avaccine to direct a successful and enduring immune response against breast cancer cells is an alluring method. Vaccine would have a few hypothetical preferences over standard therapy, including low toxicities, high specificity, and long lasting efficacy because of the establishment of immunological memory. On the other hand, Breast Cancer vaccines have failed to exhibit significant results in clinical trials as such. This reflects the inborn trouble in breaking the complex immune escaping mechanism created by tumor cells. New vaccine ought to have the capacity to evoke complex immunologic reaction including numerous immune effectors, for example, Cytotoxic and antibody secreting B cells, innate immunity effectors, and memory cells. In addition, particularly in patients with large tumor burdens and metastatic disease, combining vaccines with different procedures, for example, systemic Breast cancer treatments, passive immunotherapy, or immunomodulatory agents could expand the viability of each methodology.

Breast Cancer is immunogenic and there are a few tumor related antigens for which breast cancer vaccine have been produced. Breast cancer vaccine is intended to stimulate the immune response at different steps in the local antigen processing pathway for immune surveillance. Human epidermal growth factor receptor 2 (HER-2/neu), mucin 1 (MUC-1), and human telomerase reverse transcriptase (hTERT) are probably the most investigated antigens effectively being focused for vaccination in breast cancer patients.

Key-word: Breast Cancer, MUC-1, hTERT, HER-2/neu, USFDA, IHC, DCs, TAAs